Previous 10 | Next 10 |
home / stock / bioyf / bioyf news
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key highlights include: Second quarter (Q2) 2023 Total Company Net Revenues of $7,962,80...
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 1...
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2023 on Tuesday, August 22, 2023 after market close. A presentation on...
MISSISSAUGA, Ontario, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Inofolic ® to the Canadian marketplace. Inofolic ® is a natura...
MISSISSAUGA, Ontario, July 06, 2023 (GLOBE NEWSWIRE) -- BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the American Head and Neck Society (AHNS) 11 th International Co...
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution an...
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care pr...
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights include: First quarter (Q1) 2023 Canadian Pharmaceutical Net Revenues of $6,411,694...
2023-05-26 02:35:25 ET BioSyent ( OTCPK:BIOYF ) declares CAD 0.04/share quarterly dividend , in line with previous. Payable June 15; for shareholders of record June 2; ex-div June 1. See BIOYF Dividend Scorecard, Yield Chart, & Dividend Growth. For further de...
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15,...
News, Short Squeeze, Breakout and More Instantly...
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a Euro...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: Return on Equity for TTM March 31, 2024 was 21% as compared to 15% ...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 20...